CN101696166A - Preparation method for danshen root salvianolic acid A - Google Patents
Preparation method for danshen root salvianolic acid A Download PDFInfo
- Publication number
- CN101696166A CN101696166A CN200910169900A CN200910169900A CN101696166A CN 101696166 A CN101696166 A CN 101696166A CN 200910169900 A CN200910169900 A CN 200910169900A CN 200910169900 A CN200910169900 A CN 200910169900A CN 101696166 A CN101696166 A CN 101696166A
- Authority
- CN
- China
- Prior art keywords
- salvianolic acid
- extract
- danshen root
- preparation
- root salvianolic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- YMGFTDKNIWPMGF-AGYDPFETSA-N 3-(3,4-dihydroxyphenyl)-2-[(e)-3-[2-[(e)-2-(3,4-dihydroxyphenyl)ethenyl]-3,4-dihydroxyphenyl]prop-2-enoyl]oxypropanoic acid Chemical compound C=1C=C(O)C(O)=C(\C=C\C=2C=C(O)C(O)=CC=2)C=1/C=C/C(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 YMGFTDKNIWPMGF-AGYDPFETSA-N 0.000 title claims abstract description 84
- YMGFTDKNIWPMGF-QHCPKHFHSA-N Salvianolic acid A Natural products OC(=O)[C@H](Cc1ccc(O)c(O)c1)OC(=O)C=Cc2ccc(O)c(O)c2C=Cc3ccc(O)c(O)c3 YMGFTDKNIWPMGF-QHCPKHFHSA-N 0.000 title claims abstract description 84
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 title claims abstract description 65
- 244000132619 red sage Species 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 claims abstract description 44
- 239000007788 liquid Substances 0.000 claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 159
- 239000000284 extract Substances 0.000 claims description 99
- 240000007164 Salvia officinalis Species 0.000 claims description 38
- 239000012141 concentrate Substances 0.000 claims description 37
- 235000005412 red sage Nutrition 0.000 claims description 36
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 32
- 238000012546 transfer Methods 0.000 claims description 31
- 238000001035 drying Methods 0.000 claims description 30
- 239000000706 filtrate Substances 0.000 claims description 30
- 238000010828 elution Methods 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 17
- 239000011347 resin Substances 0.000 claims description 17
- 229920005989 resin Polymers 0.000 claims description 17
- 239000006286 aqueous extract Substances 0.000 claims description 16
- 239000012535 impurity Substances 0.000 claims description 16
- 238000004440 column chromatography Methods 0.000 claims description 15
- 238000002474 experimental method Methods 0.000 abstract description 29
- 238000000605 extraction Methods 0.000 abstract description 14
- 239000002775 capsule Substances 0.000 abstract description 8
- 239000008187 granular material Substances 0.000 abstract description 8
- 239000008188 pellet Substances 0.000 abstract description 8
- 239000006187 pill Substances 0.000 abstract description 8
- 239000007901 soft capsule Substances 0.000 abstract description 8
- 239000003826 tablet Substances 0.000 abstract description 8
- 150000007965 phenolic acids Chemical class 0.000 abstract description 6
- 230000000144 pharmacologic effect Effects 0.000 abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 241000700159 Rattus Species 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000003809 water extraction Methods 0.000 description 8
- 239000008280 blood Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 238000003672 processing method Methods 0.000 description 6
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 5
- 230000001338 necrotic effect Effects 0.000 description 5
- 210000000269 carotid artery external Anatomy 0.000 description 4
- 210000004004 carotid artery internal Anatomy 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 239000008899 fufang danshen Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 235000009048 phenolic acids Nutrition 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000415078 Anemone hepatica Species 0.000 description 3
- 101800004637 Communis Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010063837 Reperfusion injury Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 108700004675 bleomycetin Proteins 0.000 description 3
- QYOAUOAXCQAEMW-UTXKDXHTSA-N bleomycin A5 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCNCCCCN)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QYOAUOAXCQAEMW-UTXKDXHTSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- MOVRKLZUVNCBIP-RFZYENFJSA-N cortancyl Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O MOVRKLZUVNCBIP-RFZYENFJSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 210000000115 thoracic cavity Anatomy 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002767 hepatic artery Anatomy 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical group C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 1
- SNKFFCBZYFGCQN-UHFFFAOYSA-N 2-[3-[3-[1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyloxy]-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C=1C=C(O)C=2OC(C=3C=C(O)C(O)=CC=3)C(C(=O)OC(CC=3C=C(O)C(O)=CC=3)C(O)=O)C=2C=1C=CC(=O)OC(C(=O)O)CC1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010018833 Haematocoele Diseases 0.000 description 1
- 208000005873 Hematocele Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- SNKFFCBZYFGCQN-VWUOOIFGSA-N Lithospermic acid B Natural products C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-VWUOOIFGSA-N 0.000 description 1
- 101100203936 Mus musculus Srpra gene Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000002223 garnet Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000004920 hematocele of tunica vaginalis testis Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 210000000956 olfactory bulb Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a preparation method for danshen root salvianolic acid A, which is characterized in that total phenolic acid in danshen root is converted into the salvianolic acid A by using a certain method so as to greatly improve the extraction efficiency of the salvianolic acid A. The danshen root salvianolic acid A is prepared into tablets, capsules, granules, soft capsules, pellets, pills and oral liquid. Pharmacological experiments show that the salvianolic acid A has good pharmacological effects.
Description
The present invention is that application number is 200710001055.4 divides an application, and the applying date of original bill is on January 23rd, 2007, and application number is 200710001055.4, and denomination of invention is: a kind of preparation method of danshen root salvianolic acid A.
Technical field
The present invention relates to medicine, health food technology field, be specifically related to a kind of preparation method of danshen root salvianolic acid A.
Background technology
The red sage root is the root of the Labiatae salvia red sage root.Bitter, cold nature, the red sage root is one of the most frequently used medicinal material, being used for the treatment of cardiovascular and cerebrovascular diseases such as stenocardia, hypertension, coronary heart disease and apoplexy, having the effect of promoting blood circulation and removing blood stasis, nourishing blood to tranquillize the mind, cool blood row's carbuncle and toxin expelling myogenic, is Chinese medicine flavour of a drug commonly used promoting blood circulation and removing blood stasis.
The chemical ingredients of the red sage root mainly can be divided into water soluble component and fat-soluble component, red sage root water soluble ingredient has the phenolic acid structure more, be effective constituents such as salvianolic acid A, B, C, D, E, the highest in the Radix Salviae Miltiorrhizae total phenolic acids with content of danshinolic acid B, therefore, the emphasis of people's exploitation concentrates on salvianolic acid B, and content is lower, active stronger salvianolic acid A (salvianolic acid A) is ignored by people because can't carry out suitability for industrialized production.Consult document, we can learn therefore the content of salvianolic acid A in the red sage root is about 5/10000ths,, even it is extracted by a series of method, can only obtain the trace danshen root salvianolic acid A, be applied to clinical in, can not be accepted by the patient because its price is too high; But danshen root salvianolic acid A has good pharmacologically active, can be applied in medicine, the protective foods, and therefore, a lot of medical workers wish salvianolic acid A is carried out suitability for industrialized production, are developed as the patent medicine preparation.
The processing method of danshen root salvianolic acid A extraction purifying is disclosed in existing document and the patent, though can access danshen root salvianolic acid A, but its emphasis all is placed on how with on danshen root salvianolic acid A and the separate impurities, its extraction yield is very low, can't in suitability for industrialized production, realize, also can't obtain the danshen root salvianolic acid A of " patent medicine " level, this is one difficulty of pendulum in face of a lot of researchers.
Summary of the invention
For these reasons, we find by long term studies, after Radix Salviae Miltiorrhizae total phenolic acids extracted, under certain condition, Radix Salviae Miltiorrhizae total phenolic acids can be changed into danshen root salvianolic acid A, thereby improve the extraction yield of danshen root salvianolic acid A greatly, its extraction yield can reach 1%-2%, on the basis that has solved extraction yield, the formulation preparation of salvianolic acid A also is readily solved.
The invention reside in provides a kind of processing method that improves the danshen root salvianolic acid A extraction yield;
The present invention also is to provide a kind of preparation method who contains the danshen root salvianolic acid A preparation.
The present invention is achieved through the following technical solutions.
One. processing method
Danshen root salvianolic acid A extracts:
Method 1: red sage root water or ethanolic soln extract and obtain aqueous extract or alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 3.5-6.0,110-130 ℃ temperature, heated 1-6 hour, solution filters, and the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 2: red sage root water or ethanolic soln extract and obtain aqueous extract or alcohol extract, alcohol extract concentrates ethanol to most, transfer pH value to 3.5-6.0, put into the microwave extraction device, frequency is that 915MHz-2450MHz, power are 1000-15000 watt microwave extraction 0.5-2 hour, extracting liquid filtering, the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 3: red sage root water or ethanolic soln extract and obtain aqueous extract or alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 3.5-6.0,110-130 ℃ temperature, heated 1-6 hour, solution filters, and filtrate is separated first water, 10-30% Diluted Alcohol wash-out through nonpolar or low-pole macroporous resin column chromatography, remove impurity, use the ethanol elution of 30-70% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Method 4: red sage root water or ethanolic soln extract and obtain aqueous extract or alcohol extract, alcohol extract concentrates ethanol to most, transfer pH value to 3.5-6.0, put into the microwave extraction device, frequency is that 915MHz-2450MHz, power are 1000-15000 watt microwave extraction 0.5-2 hour, extracting liquid filtering, filtrate is separated through nonpolar or low-pole macroporous resin column chromatography, elder generation's water, 10-30% Diluted Alcohol wash-out are removed impurity, use the ethanol elution of 30-70% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Wherein said macroporous resin column is HPD-100, HPD-100A, HPD-300, HPD-400, HPD-400A, HPD-450, D101,1300-I, 1400 or AB-8.
Contain the pharmaceutical composition that the danshen root salvianolic acid A extract is an activeconstituents.
Formulation preparation: get above-mentioned danshen root salvianolic acid A, learn the conventional preparation that requires to be prepared into according to tablet, capsule, granule, soft capsule, pellet, pill, oral liquid medicine.
The solid preparation of the application's preparation carries out the dissolution rate experiment, and dissolution rate reaches more than 80% in the time of 45 minutes.
Two. detection method
Experimental technique:
Chromatographic column: C
18Reverse-phase chromatographic column, NUCLEODUR, 250*4.6mm, ODS;
Chromatographic condition and system suitability experiment: with the octadecylsilane chemically bonded silica is weighting agent; Flow velocity 1.0ml/min; 35 ℃ of column temperatures; Detect wavelength 286nm; Number of theoretical plate should be not less than 60000 by salvianolic acid A; With acetonitrile-0.2% aqueous acetic acid is moving phase, carries out gradient elution by following condition of gradient elution, moves 90 minutes;
In the time of 0-15 minute, the ratio of acetonitrile reduces to 80% by 10% ratio that rises to 20%, 0.2% aqueous acetic acid by 90%; In the time of 15-55 minute, the ratio of acetonitrile reduces to 70% by 20% ratio that rises to 30%, 0.2% aqueous acetic acid by 80%; In the time of 55-65 minute, the ratio of acetonitrile reduces to 50% by 30% ratio that rises to 50%, 0.2% aqueous acetic acid by 70%; In the time of 65-72 minute, the ratio of acetonitrile reduces to 20% by 50% ratio that rises to 80%, 0.2% aqueous acetic acid by 50%; In the time of 72-77 minute, the ratio 20% of ratio 80%, 0.2% aqueous acetic acid of acetonitrile; In the time of 77-80 minute, the ratio of acetonitrile rises to 90% by 80% ratio of reducing to 10%, 0.2% aqueous acetic acid by 20%; In the time of 80-90 minute, keep acetonitrile-0.2% aqueous acetic acid to carry out wash-out with 10: 90 ratio;
The preparation of reference substance solution: precision takes by weighing the salvianolic acid A reference substance in volumetric flask, adds dissolve with methanol and shakes up, and be diluted to scale;
The preparation of sample solution: sample thief adds dissolve with methanol and shakes up; Or precision measures or takes by weighing preparation, adds dissolve with methanol and shakes up, and be diluted to scale;
Assay method: the accurate reference substance solution of drawing, inject liquid chromatograph, the record color atlas; The accurate sample solution of drawing injects liquid chromatograph, calculates peak area ratio.
Three. the extraction yield experiment
Experimental technique: get red rooted salvia, according to above-mentioned check and analysis experimental technique, measure danshen root salvianolic acid A content, be divided into six equal portions, portion is method (Chinese patent CN1397276A traditionally, scheme 1) obtains the danshen root salvianolic acid A extract, a according to processing method (Chinese patent CN1830947, scheme 2), other four parts obtain the danshen root salvianolic acid A extract according to the application's processing method (being followed successively by scheme 3-6) respectively, according to salvianolic acid A weight in the above-mentioned check and analysis experimental calculation danshen root salvianolic acid A extract, according to the extraction yield of salvianolic acid A weight calculating different process method, experimental result sees Table 1:
The extraction yield of table 1 different process method salvianolic acid A
Experiment conclusion: show by above-mentioned experiment, the extraction yield that the application's processing method obtains salvianolic acid A has improved more than 100 times than the extraction yield of salvianolic acid A in the prior art, this can't realize by simple extraction and purification process, must Radix Salviae Miltiorrhizae total phenolic acids be changed into salvianolic acid A by certain conversion, could fundamentally improve the extraction yield of salvianolic acid A.
Four. pharmacological evaluation
Experiment 1
1. to the provide protection of anesthetized rat myocardial ischemia-reperfusion injury
Experimental technique:
Get the healthy SD rat, body weight 240-260g, random packet: blank group, FUFANG DANSHEN PIAN group, the application's solid preparation of salvianolic acid A of red sage root group.Place the pre-raising of equivalent environment 2 days, free diet.After pre-raising finishes, test, animal is weighed, and 20% urethane is pressed the 0.6ml/100g abdominal injection, after treating that anesthesia is satisfied, lie on the back and be fixed on the mouse plate, trachea cannula connects respirator, by 10～12ml Tidal volume, 70 times/minute frequency is exhaled, and continuous positive pressure breathing is inhaled: exhale than being 1: 1.Adjust respiration parameter according to the respiratory rate and the degree of depth.Connect electrocardiograph subsequently, survey normal ECG.Cut off front field of operation hair, iodine disinfection, cut off skin, subcutis, front muscle and manadesma 3～4cm, it is long to separate intercostal muscle 3cm with the 18# vascular clamp along the 3rd intercostal passivity, open thoracic cavity and pericardium, recording ecg, strut 3,4 ribs, refer to hold thoracic cavity, rat right side with left hand four, the assistant upwards pushes away thymus gland with the ophthalmology tweezer, finds ligation sign blood vessel great cardiac vein between left auricle of heart and pulmonary conus, the 2mm place is with there not being wound roundlet pin band 6-0 silk thread threading below left auricle of heart, depth of needle is 1～1.5mm, wide 2～3mm, recording ecg behind the threading, give corresponding soup through the tail vein, recording ecg behind the administration 10min, and with one the band groove little plastics pipe pad at the ligation position, the ligation thereon of two rear line heads.At once recording ecg after the ligation is cyanosis or the II S-T section back of a bow that leads with left chamber antetheca and upwards raises greater than 0.1mv and be that ligation successfully indicates (it is superseded that the S-T section does not have the changer) more than the lasting 0.5h.10min recording ecg is once more cut off ligature behind the ligation 30min after the ligation, realizes perfusion again, and record pours into electrocardiogram(ECG at once again, removes in the thoracic cavity layer-by-layer suture wall of the chest behind the hematocele, removes respirator, animal recovery autonomous respiration, and incision of trachea does not process.Irritate again at once, 10min, 20min, 40min, 1h, 2h, 3h recording ecg respectively.With heart after refrigerator and cooled is frozen 10min, from the apex of the heart entad the parallel coronary sulcus direction in the end 5 of equal thickness are cut in left chamber, put into the 1%TTC dye liquor, 37 ℃ of dyeing 10min, the necrotic area is not a garnet, the necrotic area is canescence.Digital camera is taken pictures.Weighed respectively in necrotic area and non-necrotic area, calculate the per-cent that the necrotic area accounts for left ventricular mass, i.e. infarction size.
Table 4 solid preparation of salvianolic acid A is to the influence of myocardial ischemia myocardial infarct size (%) due to the logical rat ramus descendens anterior arteriae coronariae sinistrae of ligation/again (x ± s)
Annotate: compare with the blank group,
*P＜0.01; Compare #P＜0.05 with positive FUFANG DANSHEN PIAN group
Experiment 2
Research to the provide protection of intraluminal middle cerebral artery occlusion in rats ischemical reperfusion injury
Experimental technique:
Animal random packet: blank group, FUFANG DANSHEN PIAN group, the application's danshen root salvianolic acid A preparation group.The continuous gastric infusion of each dosage group 3 days was made middle cerebral artery occlusion (MCAO) model with improvement line bolt method in 20 minutes behind the 4th day medicine.Behind the rat anesthesia, it is fixing that it is lain on the back.Separate right carotid (CCA), internal carotid artery (ICA) and external carotid artery (ECA), ligation ECA and CCA, after closing the ICA distal end with bulldog clamp folder, make a kerf in ECA and ICA crotch rapidly, insert the nylon wire (diameter is 0.25mm, marks apart from pommel 18mm place, is stained with heparin solution before the insertion) that an end is heated into smooth, spherical and has been coated with 0.1% poly-lysine, depth of penetration is 18mm, realizes that middle cerebral artery occlusion causes cerebral ischemia.Ligation ingress, nylon wire are stayed about 1cm, skin suture outward.Lift extremely slightly resistance of institute's the end of a thread that stays after 2 hours gently, realize that arteria cerebri media pours into again, modeling is finished.At ischemic 2h with pour into the body temperature of keeping rat in the 1h with electric blanket again, body temperature maintains 36.5～37.5 ℃ of anus temperature.The animal inclusion criteria is pressed Longa Pyatyi point system, gets the neural function behavior scoring and be 1,2,3,4 minute animal, (0 minute: the impassivity defective symptom; 1 minute: the offside forelimb can not stretch fully; 2 minutes: to sideway swivel; 3 minutes: topple over to offside; 4 minutes: can not oneself walk or stupor).The cerebral infarction scope is measured, rat model pours into 24h again, after the study of behaviour scoring, broken end is got brain, removes olfactory bulb, cerebellum and low brain stem, and remainder is at-20 ℃ of freezing 10min of refrigerator, crownly on ice pan be cut into 6, rapidly the brain sheet is placed the TTC dye liquor, 37 ℃ of lucifuge temperature are incubated 1h, take out to be placed on the 24h that keeps in Dark Place in 10% formalin.The non-ischemic region in dyed back is a rose, and infarct is a white.White organized carefully to dig down weigh, account for full brain weight per-cent as the cerebral infarction scope with blocking tissue's weight.
Brain water content is measured: after TTC dyeing is weighed, brain placed oven dry 12h claims dry weight in 120 ℃ of vacuum driers.Brain water content=(brain weight in wet base-brain stem is heavy)/brain weight in wet base * 100%.Experimental result sees table 5 for details.
The influence of table 5 pair intraluminal middle cerebral artery occlusion in rats ischemical reperfusion injury rat cerebral infarction scope and brain water content (X ± S)
Annotate: compare with the blank group,
*P＜0.01; Compare #P＜0.05 with positive FUFANG DANSHEN PIAN group
Experiment 3
To CCl
4X causes the influence of rat liver fibrosis
Experimental technique: select 60 of male and healthy Wistar rats, body weight 180-200g, all divide normal group, colchicine group (0.17mg/kg), the application's danshen root salvianolic acid A preparation group at random with rat, except that the normal control group, all the other respectively organize rat first in subcutaneous injection CCl
45ml/kg, 2 back subcutaneous injection 40%CCl4 sweet oil 3ml/kg, totally 6 weeks weekly later on.Except that normal group, the 1st～2 week, each group all gave the Semen Maydis powder feed that 20% lard adds 0.5% cholesterol at experimental session, and the 3rd～6 week raised with normal diet.Each administration group is irritated the soup that stomach gives corresponding dosage simultaneously when modeling begins, administration volume 1ml/100g, and administration time is totally 12 weeks.Each is organized after the medication cycle finishes, and cuts open the belly under the etherization, through the lower chamber dooor venous blood collection, detects Serum ALT, AST, Alb respectively, and gets a part of hepatic tissue and make liver homogenate, is used to detect oxyproline (Hyp) content.Other gets hepatic tissue and does HE dyeing and be used for pathological study.Experimental result sees Table 6:
The influence of Hyp in the table 6 pair Liver Fibrosis Model liver tissues of rats (X ± S)
Annotate: compare with the blank group,
*P＜0.01;
Experiment 4
Influence to the mouse pulmonary fibrosis model
Experimental technique:
Age in animal: 8-1 week, male, Kunming mouse, body weight 18-22g.Reagent: bleomycin for inj A5, Hebei, Tianjin pharmaceutical factory, prednisone acetate tablets: fairy house pharmaceutical Co. Ltd produces, and the time spent grinding powder is made into 50% suspension with dissolved in distilled water.PBS liquid, oneself is prepared.Adopt bleomycin A5 to duplicate animal diffuse interstitial pulmonary fibrosis model.Mouse is lain on the back on experiment table after with etherization, and fixing head and four limbs cut skin of neck, by the disposable injection bleomycin A5 of tracheae solution 0.05ml (pastille 0.1mg, 5mg/kg).Skin suture after injection finishes, mouse is upright, rotation make soup uniform distribution in lung as far as possible.The strict aseptic technique of surgical procedure.The blank group is in kind injected equivalent physiologic saline for substitute bleomycin A5, the clear-headed back of animal ad libitum access.The mouse modeling is divided into 6 groups at random after 24 hours, be respectively blank group, Prednisone acetate group (6.5mg/kg), the application's solid preparation group.The blank group is irritated stomach and is given distilled water 0.2ml/10g, every day three times; Positive controls is irritated stomach and is given Prednisone acetate, 6.5mg/kg, 0.2ml/10g, every day three times after the modeling; The administration group is irritated the soup that stomach gives each corresponding dosage by 0.2ml/10g after the modeling.
More than each the group, successive administration 28 days.The result sees table 7 for details.
The influence of table 7 pair pulmonary fibrosis model mouse lung coefficient (X ± S)
Annotate: compare with the blank group,
*P＜0.01
Experiment 5
The MTT reduction method detects the preparation anti-tumor activity test
Experiment material:
MTT: with phosphate buffered saline buffer (PBS) the dissolving MTT final concentration 5mg/ml of 0.01mol/L, filtration sterilization, 4 ℃ keep in Dark Place after the packing.
The preparation of MTT lysate: the 80g sodium laurylsulfonate is dissolved in the N-N-dimethyl methyl phthalein amine of 200ml, and the heating in water bath hydrotropy adds 200ml distilled water, mixes with 1N hydrochloric acid (1: 1) with 80% acetate and transfers pH to 4.7.
Cell strain is selected for use: human normal cell line strain, human hepatoma cell strain and National People's Congress's sclc cell line.
Experimental technique: single cell suspension is inoculated in 96 orifice plates (with the RPM-1640 basic medium with cell dilution to 30000/ml, every hole adds 200 μ l and dilutes good cell), cultivates 24 hours under 37 ℃, 5% carbonic acid gas saturated humidity; Every group of four parallel samples; Remove substratum, get new preparation substratum and prepare cancer therapy drug (the application's preparation) solution by series concentration, every hole 20 μ l cultivated 48 hours; Every hole adds the MTT20 μ l of 2mg/ml, hatches 4 hours; Nutrient solution in the sucking-off hole (as far as possible fully) adds DMSO liquid (150 μ l/ hole), vibrates 10 minutes, and crystallisate is fully dissolved; Microplate reader detects each hole OD value, (detecting wavelength 560nm); Draw the cell viability graphic representation, obtain the IC50 value.Experimental result is as shown in table 8:
Table 8 cytotoxicity experiment result
Brief summary: the application's solid preparation has stronger cell toxicant, and its toxicity has certain selectivity to normal cell and cancer cells, and the application's solid preparation can be used for making each antitumor drug.
Experiment 6
Comparison to the rats'liver tumor suppression
Laboratory animal: rat, 150g-180g, male and female are regardless of.
Experiment medicine: physiological saline; The present invention respectively organizes preparation; Commercially available sodium cantharidinate tablet.
Experimental technique: get rat and be divided into physiological saline group, sodium cantharidinate tablet group, preparation group of the present invention, make W
256Liver in inoculation, inoculate after 7 days, press the dosage intraperitoneal injection of anesthesia of 35mg/kg with vetanarcol, fixing, cutting open the belly exposes liver, tumor surface maximum diameter (a) and path (b) are pressed (a*b on the measurement liver
2)/2=V (gross tumor volume).Separate stomach, arteria duodenalis, arteria hepatica communis and proper hepatic artery, ligation stomach, arteria duodenalis far-end, with silver brain clip blocking-up arteria hepatica communis, in sending into proper hepatic artery again at the gastroduodenal artery upper cut and after inserting external diameter 0.3mm conduit under the operating loupe, inject respectively by the experiment grouping then and be subjected to the reagent thing, postoperative tube drawing ligation gastroduodenal artery, decontrol the arteria hepatica communis silver brain clip, sew up the incision again, place animal housing to wait to revive rat, continue breeding observing, performed the operation back 8 days, detect gross tumor volume by last method, experimental result sees Table 9:
Table 9 is respectively organized preparation to the rejection ratio of tumour
Annotate: compare with the physiological saline group
*P＜0.01;
Experiment 7
Anti-ageing experiment
Experimental technique:
With aged Shanghai is the mouse random packet, 14/group, and male and female half and half, the administration group is irritated stomach preparation 15mg/kg of the present invention, 3 weeks of administration altogether every day.Blood 50 μ l are got in the mouse docking, measure the activity of SOD according to the autoxidizable method of pyrogallol.With the mouse sacrificed by decapitation, take out liver, inhale with filter paper and remove residual blood, shred and weigh, add physiological saline, be prepared into 1% homogenate, adopt the thiobarbituricacid method to measure the content of LPO in the hepatic tissue.Experimental result sees Table 10:
Table 10 solid preparation is to the influence of SOD, LPO
Annotate: compare with control group
*P＜0.01,
*P＜0.05; Compare #P＜0.05 with positive controls
Five. preparation embodiment
Embodiment 1
Method 1: the red sage root obtains aqueous extract with water extraction, transfers pH value to 3.5,110 ℃ of temperature, heats 1 hour, and solution filters, and the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 2: the red sage root obtains aqueous extract with water extraction, transfers pH value to 3.5, puts into the microwave extraction device, and frequency is that 915MHz, power are 1000 watts microwave extraction 0.5 hour, extracting liquid filtering, and the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 3: the red sage root obtains aqueous extract with water extraction, transfer pH value to 3.5,110 ℃ of temperature, heated 1 hour, solution filters, filtrate is separated through the HPD-100 macroporous resin column chromatography, elder generation's water, 10% Diluted Alcohol wash-out are removed impurity, use the ethanol elution of 30% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Method 4: the red sage root obtains aqueous extract with water extraction, transfers pH value to 3.5, puts into the microwave extraction device, frequency is that 915MHz, power are 1000 watts microwave extraction 0.5 hour, extracting liquid filtering, filtrate is separated through the HPD-100A macroporous resin column chromatography, first water, 10% Diluted Alcohol wash-out, remove impurity, use the ethanol elution of 30% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Formulation preparation: get above-mentioned danshen root salvianolic acid A, learn the conventional preparation that requires to be prepared into according to tablet, capsule, granule, soft capsule, pellet, pill, oral liquid medicine.
Embodiment 2
Method 1: the red sage root extracts with 70% ethanolic soln and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 4.5,120 ℃ of temperature, heats 3 hours, and solution filters, and the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 2: the red sage root extracts with 70% ethanolic soln and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 4.5, put into the microwave extraction device, frequency is that 2450MHz, power are 10000 watts microwave extraction 1 hour, extracting liquid filtering, the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 3: the red sage root extracts with 70% ethanolic soln and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 4.5,120 ℃ of temperature, heated 3 hours, solution filters, and filtrate is separated through the HPD-300 macroporous resin column chromatography, first water, 20% Diluted Alcohol wash-out, remove impurity, use the ethanol elution of 50% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Method 4: the red sage root extracts with 70% ethanolic soln and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 4.5, put into the microwave extraction device, frequency is that 2450MHz, power are 10000 watts microwave extraction 1 hour, extracting liquid filtering, filtrate is separated through the HPD-400 macroporous resin column chromatography, elder generation's water, 20% Diluted Alcohol wash-out are removed impurity, use the ethanol elution of 50% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Formulation preparation: get above-mentioned danshen root salvianolic acid A, learn the conventional preparation that requires to be prepared into according to tablet, capsule, granule, soft capsule, pellet, pill, oral liquid medicine.
Embodiment 3
Method 1: the red sage root extracts with 80% ethanolic soln and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 6.0,130 ℃ of temperature, heats 6 hours, and solution filters, and the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 2: the red sage root extracts with 80% ethanolic soln and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 6.0, put into the microwave extraction device, frequency is that 2450MHz, power are 15000 watts microwave extraction 2 hours, extracting liquid filtering, the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 3: the red sage root extracts with 80% ethanolic soln and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 6.0,130 ℃ of temperature, heated 6 hours, solution filters, and filtrate is separated through the HPD-400A macroporous resin column chromatography, first water, 30% Diluted Alcohol wash-out, remove impurity, use the ethanol elution of 70% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Method 4: the red sage root extracts with 80% ethanolic soln and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 6.0, put into the microwave extraction device, frequency is that 2450MHz, power are 15000 watts microwave extraction 2 hours, extracting liquid filtering, filtrate is separated through the HPD-450 macroporous resin column chromatography, elder generation's water, 30% Diluted Alcohol wash-out are removed impurity, use the ethanol elution of 70% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Formulation preparation: get above-mentioned danshen root salvianolic acid A, learn the conventional preparation that requires to be prepared into according to tablet, capsule, granule, soft capsule, pellet, pill, oral liquid medicine.
Embodiment 4
Method 1: the red sage root obtains aqueous extract with water extraction, transfers pH value to 4.0,115 ℃ of temperature, heats 2 hours, and solution filters, and the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 2: the red sage root extracts with 20% ethanolic soln and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 4.0, put into the microwave extraction device, frequency is that 915MHz, power are 2000 watts microwave extraction 0.8 hour, extracting liquid filtering, the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 3: the red sage root extracts with 25 ethanolic solns and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 4.0,115 ℃ of temperature, heated 1.5 hours, solution filters, and filtrate is separated through the D101 macroporous resin column chromatography, first water, 15% Diluted Alcohol wash-out, remove impurity, use the ethanol elution of 35% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Method 4: the red sage root obtains aqueous extract with water extraction, transfers pH value to 4.0, puts into the microwave extraction device, frequency is that 915MHz, power are 2500 watts microwave extraction 0.8 hour, extracting liquid filtering, filtrate is separated through the 1300-I macroporous resin column chromatography, first water, 15% Diluted Alcohol wash-out, remove impurity, use the ethanol elution of 35% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Formulation preparation: get above-mentioned danshen root salvianolic acid A, learn the conventional preparation that requires to be prepared into according to tablet, capsule, granule, soft capsule, pellet, pill, oral liquid medicine.
Embodiment 5
Method 1: the red sage root extracts with 75% ethanolic soln and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 5.5,125 ℃ of temperature, heats 5.5 hours, and solution filters, and the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 2: red sage root water obtains aqueous extract, transfers pH value to 5.0, puts into the microwave extraction device, and frequency is that 2450MHz, power are 14500 watts microwave extraction 1.8 hours, extracting liquid filtering, and the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 3: the red sage root obtains aqueous extract with water extraction, transfer pH value to 5.5,125 ℃ of temperature, heated 5 hours, solution filters, filtrate is separated through the AB-8 macroporous resin column chromatography, elder generation's water, 25% Diluted Alcohol wash-out are removed impurity, use the ethanol elution of 65% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Method 4: the red sage root extracts with 75% ethanolic soln and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 5.5, put into the microwave extraction device, frequency is that 2450MHz, power are 14500 watts microwave extraction 1.8 hours, extracting liquid filtering, filtrate is separated through 1400 macroporous resin column chromatographies, elder generation's water, 25% Diluted Alcohol wash-out are removed impurity, use the ethanol elution of 65% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Formulation preparation: get above-mentioned danshen root salvianolic acid A, learn the conventional preparation that requires to be prepared into according to tablet, capsule, granule, soft capsule, pellet, pill, oral liquid medicine.
Embodiment 6
Method 1: the red sage root obtains aqueous extract with water extraction, transfers pH value to 4.5,120 ℃ of temperature, heats 4.5 hours, and solution filters, and the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 2: the red sage root extracts with 70% ethanolic soln and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 4.5, put into the microwave extraction device, frequency is that 2450MHz, power are 10000 watts microwave extraction 1 hour, extracting liquid filtering, the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 3: the red sage root extracts with 70% ethanolic soln and obtains aqueous extract or alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 4.5,120 ℃ of temperature, heated 3 hours, solution filters, and filtrate is separated through 1400 macroporous resin column chromatographies, first water, 20% Diluted Alcohol wash-out, remove impurity, use the ethanol elution of 50% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Method 4: the red sage root extracts with 70% ethanolic soln and obtains alcohol extract, and alcohol extract concentrates ethanol to the greatest extent, transfers pH value to 4.5, put into the microwave extraction device, frequency is that 2450MHz, power are 9000 watts microwave extraction 1.5 hours, extracting liquid filtering, filtrate 1300-I macroporous resin column chromatography separates, elder generation's water, 20% Diluted Alcohol wash-out are removed impurity, use the ethanol elution of 45% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract;
Formulation preparation: get above-mentioned danshen root salvianolic acid A, learn the conventional preparation that requires to be prepared into according to tablet, capsule, granule, soft capsule, pellet, pill, oral liquid medicine.
Claims (2)
1. the preparation method of a danshen root salvianolic acid A is characterized in that:
Danshen root salvianolic acid A extracts:
Method 1: red sage root water or ethanolic soln extract and obtain aqueous extract or alcohol extract, alcohol extract concentrates ethanol to most, transfer pH value to 3.5-6.0, put into the microwave extraction device, frequency is that 915MHz-2450MHz, power are 1000-15000 watt microwave extraction 0.5-2 hour, extracting liquid filtering, the filtrate concentrate drying obtains the danshen root salvianolic acid A extract;
Method 2: red sage root water or ethanolic soln extract and obtain aqueous extract or alcohol extract, alcohol extract concentrates ethanol to most, transfer pH value to 3.5-6.0, put into the microwave extraction device, frequency is that 915MHz-2450MHz, power are 1000-15000 watt microwave extraction 0.5-2 hour, extracting liquid filtering, filtrate is separated through nonpolar or low-pole macroporous resin column chromatography, elder generation's water, 10-30% Diluted Alcohol wash-out are removed impurity, use the ethanol elution of 30-70% concentration again, collect elutriant, reclaim ethanol to most, drying obtains the danshen root salvianolic acid A extract.
2. the preparation method of a kind of danshen root salvianolic acid A according to claim 1, wherein said macroporous resin column are HPD-100, HPD-100A, HPD-300, HPD-400, HPD-400A, HPD-450, D101,1300-I, 1400 or AB-8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101699008A CN101696166B (en) | 2007-01-23 | 2007-01-23 | Preparation method of salvianolic acid A from salvia miltiorrhiza |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101699008A CN101696166B (en) | 2007-01-23 | 2007-01-23 | Preparation method of salvianolic acid A from salvia miltiorrhiza |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100010554A Division CN101230003B (en) | 2007-01-23 | 2007-01-23 | Preparation method of salvia miltiorrhiza tanshinoate A |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101696166A true CN101696166A (en) | 2010-04-21 |
| CN101696166B CN101696166B (en) | 2012-05-09 |
Family
ID=42141309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101699008A Expired - Fee Related CN101696166B (en) | 2007-01-23 | 2007-01-23 | Preparation method of salvianolic acid A from salvia miltiorrhiza |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101696166B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101849922A (en) * | 2010-06-08 | 2010-10-06 | 广东药学院 | Optimization method of salvianolic acid membrane controlled release pill prescription and preparation method of pill |
| CN106074487A (en) * | 2016-06-28 | 2016-11-09 | 烟台大学 | Salvianolic acid A application in preparation treatment acute injury of kidney medicine |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1397276A (en) * | 2002-08-07 | 2003-02-19 | 沈阳药科大学 | Preparing process and medical application of SLA-A contained in red sage root and its composition |
| CN100420665C (en) * | 2006-04-21 | 2008-09-24 | 王国振 | Method for extracting 'Danfen' phenolic acid-A |
| CN1887849A (en) * | 2006-07-13 | 2007-01-03 | 正大青春宝药业有限公司 | Salvianolic acid A preparing process |
-
2007
- 2007-01-23 CN CN2009101699008A patent/CN101696166B/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101849922A (en) * | 2010-06-08 | 2010-10-06 | 广东药学院 | Optimization method of salvianolic acid membrane controlled release pill prescription and preparation method of pill |
| CN106074487A (en) * | 2016-06-28 | 2016-11-09 | 烟台大学 | Salvianolic acid A application in preparation treatment acute injury of kidney medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101696166B (en) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101230003B (en) | Preparation method of salvia miltiorrhiza tanshinoate A | |
| CN101311160B (en) | Method for preparing red sage root salviandic acid A | |
| CN100999470B (en) | Salvia minium phenolic acid A and process of preparing preparation and use | |
| CN100569219C (en) | A kind of pharmaceutical composition that is used for oral formulations and preparation method thereof | |
| CN101224274A (en) | Medicine compounds of pericarp trichosanthis, longstamen onion bulb extract and preparing method thereof | |
| CN1762967B (en) | Enoxolone derivative, preparation method and uses | |
| CN101033245B (en) | Preparation method and application of pedunculoside | |
| CN1931236B (en) | Medicine composition of red sage and rhodiola root | |
| CN101278939B (en) | Medicament composition for curing cardiovascular and cerebrovascular diseases and method of preparing the same | |
| CN101759672B (en) | Salvianolic acid B in radix salviae miltiorrhizae | |
| CN101099753A (en) | Preparation method and application for general saponin of cortex ilecis rotundae | |
| CN101283999B (en) | Medicinal composition mainly for curing cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN101696166B (en) | Preparation method of salvianolic acid A from salvia miltiorrhiza | |
| CN1994277B (en) | Solid preparation of salvianolic acid A of red sage root and preparation process thereof | |
| CN100467025C (en) | Use of asiaticoside in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN101293009A (en) | Pharmaceutical composition | |
| CN101176751B (en) | Pharmaceutical composition of red sage root and cassia twig | |
| CN102125576A (en) | Application of liquiritin in preparing medicine for treating cardiovascular and cerebrovascular diseases | |
| CN101152246B (en) | Pharmaceutical composition for cardiovascular and cerebrovascular diseases and method for preparing the same | |
| CN100496481C (en) | Medicinal composition for treating cardio-cerebral-vascular disease and its preparing method | |
| CN101019824B (en) | Preparation method of oral medicine composition containing salvianolic acid | |
| CN101292987A (en) | Pharmaceutical combination | |
| CN1985881A (en) | Preparing process and application of compound red sage and chuanxiong rhizome oral preparation | |
| CN1582946B (en) | Use of centellosic acid derivative in preparation of medicines for diseases of cardio-cerebral blood vessels | |
| CN104825505B (en) | The Actinidia valvata leaf composition to resist myocardial ischemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Bencao Tianyuan Pharmaceutical Research Inst., Beijing Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice |
Addressee: Bencao Tianyuan Pharmaceutical Research Inst., Beijing Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Bencao Tianyuan Pharmaceutical Research Inst., Beijing Document name: Notification of Termination of Patent Right |
|
| DD01 | Delivery of document by public notice | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120509 Termination date: 20180123 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |